1c5o

From Proteopedia

---

Revision as of 14:11, 12 November 2007

proteopedia linkproteopedia link

spinqualitylabelsall models 1c5o, resolution 1.90Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR

Contents 1 Overview 2 Disease 3 About this Structure 4 Reference

Overview

BACKGROUND: Urokinase-type plasminogen activator (uPA) is a protease, associated with tumor metastasis and invasion. Inhibitors of uPA may have, potential as drugs for prostate, breast and other cancers. Therapeutically, useful inhibitors must be selective for uPA and not appreciably inhibit, the related, and structurally and functionally similar enzyme, tissue-type, plasminogen activator (tPA), involved in the vital blood-clotting cascade., RESULTS: We produced mutagenically deglycosylated low molecular weight uPA, and determined the crystal structure of its complex with, 4-iodobenzo[b]thiophene 2-carboxamidine (K(i) = 0.21 +/- 0.02 microM). To, probe the structural determinants of the affinity and selectivity of this, inhibitor for uPA we also determined the structures of its trypsin and, thrombin complexes, of apo-trypsin, apo-thrombin and apo-factor Xa, and of, uPA, trypsin and thrombin bound by compounds that are less effective uPA, inhibitors, benzo[b]thiophene-2-carboxamidine, thieno[2,3-b]-pyridine-2-carboxamidine and benzamidine. The K(i) values of, each inhibitor toward uPA, tPA, trypsin, tryptase, thrombin and factor Xa, were determined and compared. One selectivity determinant of the, benzo[b]thiophene-2-carboxamidines for uPA involves a hydrogen bond at the, S1 site to Ogamma(Ser190) that is absent in the Ala190 proteases, tPA, thrombin and factor Xa. Other subtle differences in the architecture of, the S1 site also influence inhibitor affinity and enzyme-bound structure., CONCLUSIONS: Subtle structural differences in the S1 site of uPA compared, with that of related proteases, which result in part from the presence of, a serine residue at position 190, account for the selectivity of small, thiophene-2-carboxamidines for uPA, and afford a framework for, structure-based design of small, potent, selective uPA inhibitors.

Disease

Known diseases associated with this structure: Dysprothrombinemia OMIM:[176930], Hyperprothrombinemia OMIM:[176930], Hypoprothrombinemia OMIM:[176930]

About this Structure

1C5O is a Protein complex structure of sequences from Homo sapiens with NA and BAM as ligands. Active as Thrombin, with EC number 3.4.21.5 Full crystallographic information is available from OCA.

Reference

Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator., Katz BA, Mackman R, Luong C, Radika K, Martelli A, Sprengeler PA, Wang J, Chan H, Wong L, Chem Biol. 2000 Apr;7(4):299-312. PMID:10779411

Page seeded by OCA on Mon Nov 12 16:17:39 2007